Annual Cash & Cash Equivalents
$78.64 M
-$27.13 M-25.65%
December 31, 2023
Summary
- As of February 7, 2025, YMAB annual cash & cash equivalents is $78.64 million, with the most recent change of -$27.13 million (-25.65%) on December 31, 2023.
- During the last 3 years, YMAB annual cash & cash equivalents has fallen by -$36.00 million (-31.40%).
- YMAB annual cash & cash equivalents is now -62.04% below its all-time high of $207.14 million, reached on December 31, 2019.
Performance
YMAB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$68.12 M
-$9.68 M-12.45%
September 30, 2024
Summary
- As of February 7, 2025, YMAB quarterly cash and cash equivalents is $68.12 million, with the most recent change of -$9.68 million (-12.45%) on September 30, 2024.
- Over the past year, YMAB quarterly cash and cash equivalents has dropped by -$10.52 million (-13.37%).
- YMAB quarterly cash and cash equivalents is now -73.00% below its all-time high of $252.27 million, reached on March 31, 2021.
Performance
YMAB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
YMAB Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -25.6% | -13.4% |
| 3 y3 years | -31.4% | -35.6% |
| 5 y5 years | -46.8% | -35.6% |
YMAB Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -56.7% | at low | -62.5% | at low |
| 5 y | 5-year | -62.0% | at low | -73.0% | at low |
| alltime | all time | -62.0% | +366.0% | -73.0% | at low |
Y-mAbs Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $68.12 M(-12.4%) |
| Jun 2024 | - | $77.81 M(+2.7%) |
| Mar 2024 | - | $75.75 M(-3.7%) |
| Dec 2023 | $78.64 M(-25.6%) | $78.64 M(-9.2%) |
| Sep 2023 | - | $86.57 M(-1.5%) |
| Jun 2023 | - | $87.91 M(-5.1%) |
| Mar 2023 | - | $92.63 M(-12.4%) |
| Dec 2022 | $105.76 M(-41.7%) | $105.76 M(-7.7%) |
| Sep 2022 | - | $114.53 M(-14.3%) |
| Jun 2022 | - | $133.66 M(-14.7%) |
| Mar 2022 | - | $156.72 M(-13.7%) |
| Dec 2021 | $181.56 M | $181.56 M(-15.8%) |
| Sep 2021 | - | $215.73 M(-7.6%) |
| Jun 2021 | - | $233.59 M(-7.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2021 | - | $252.27 M(+120.1%) |
| Dec 2020 | $114.63 M(-44.7%) | $114.63 M(-12.7%) |
| Sep 2020 | - | $131.27 M(-17.0%) |
| Jun 2020 | - | $158.06 M(-14.9%) |
| Mar 2020 | - | $185.77 M(-10.3%) |
| Dec 2019 | $207.14 M(+40.1%) | $207.14 M(+110.9%) |
| Sep 2019 | - | $98.19 M(-18.3%) |
| Jun 2019 | - | $120.16 M(-10.5%) |
| Mar 2019 | - | $134.25 M(-9.2%) |
| Dec 2018 | $147.84 M(+63.4%) | $147.84 M(-9.5%) |
| Sep 2018 | - | $163.29 M(+132.8%) |
| Jun 2018 | - | $70.15 M(-22.5%) |
| Dec 2017 | $90.48 M(+436.2%) | $90.48 M |
| Dec 2016 | $16.88 M | - |
FAQ
- What is Y-mAbs Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual cash & cash equivalents year-on-year change?
- What is Y-mAbs Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Y-mAbs Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of YMAB is $78.64 M
What is the all time high annual cash & cash equivalents for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual cash & cash equivalents is $207.14 M
What is Y-mAbs Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, YMAB annual cash & cash equivalents has changed by -$27.13 M (-25.65%)
What is Y-mAbs Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of YMAB is $68.12 M
What is the all time high quarterly cash and cash equivalents for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly cash and cash equivalents is $252.27 M
What is Y-mAbs Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, YMAB quarterly cash and cash equivalents has changed by -$10.52 M (-13.37%)